This site is intended for healthcare professionals
CDK 4/6 banner image
CDK4/6 inhibitors in breast cancer

Quiz and Evaluation

Read time: 5 mins
Last updated:22nd Aug 2023
Published:22nd Aug 2023

Please complete the following evaluation form to receive 1 CME credit

This short form consists of a post-roundtable multiple choice quiz, followed by a brief feedback form. It will take 5 minutes to complete. A certificate will be issued and sent to the email provided in your profile within 5 working days.

1. What is currently the only approved CDK4/6 inhibitor for treating early breast cancer?
2. Approval of abemaciclib for use in people with high-risk HR+/HER2− early breast cancer was based on clinical trial data from which study?
3. What PARP inhibitor is recommended for people with early breast cancer, BRCA mutation and a high risk of recurrence?
4. What topics in CDK4/6 inhibitors for treating early breast cancer would you like to learn more about?

Quality of the ELM 

Quality of the ELM 

How useful for your professional activity did you find this roundtable?

What was your overall impression of this roundtable?

What was your overall impression of this roundtable?

Programme
Organisation

Relevance of the material

Relevance of the material

Did the material fulfil your educational goals and expected learning outcomes?
Was the presented information well balanced and consistently supported by a valid scientific evidence base?

How useful to you personally was each module?

How useful to you personally was each module?

Advances with CDK4/6 inhibitors in the EBC treatment landscape
Exploring the safety and tolerability of CDK4/6 inhibitors in EBC
Panel discussion: Optimal use of CDK4/6 inhibitors in EBC
Choosing the right treatment for EBC at high risk of recurrence
Panel discussion: Choosing the right treatment for EBC at high risk of recurrence – implementing guideline recommendations

Suitability of formats used during the roundtable

Suitability of formats used during the roundtable

Was there adequate time available for learner engagement?

Ways the roundtable affects clinical practice

Ways the roundtable affects clinical practice

Will the information you learnt be implemented in your practice?

Commercial bias

Commercial bias

Did all the faculty members provide their potential conflict of interest declaration with the sponsor(s) as a second slide of their presentation?
Do you agree that the information was overall free of commercial and other bias?
I am happy to be contacted at a future date to share how learnings from this event have affected my clinical practice